ReviewWorld journal of gastroenterology2024
National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma.
Review in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of preoperative biliary drainage in patients with Hilar Cholangiocarcinoma: a systematic review and meta-analysis.International journal of surgery (London, England) · 2025Pooled it
- A practical nomogram for predicting survival in patients with extrahepatic cholangiocarcinoma: a population-based cohort study.Journal of gastrointestinal oncology · 2026Article
- Evaluating the performance of multiphasic CT in assessing biliary tumor extent and resectability in perihilar cholangiocarcinoma: insights from a Western population.Abdominal radiology (New York) · 2026Article
- A case of chronic cholangitis caused by calculi with foreign matter mimicking perihilar cholangiocarcinoma.Journal of surgical case reports · 2026Article
- Association Between Metabolic Syndrome and Long-Term Prognosis in Patients with Perihilar Cholangiocarcinoma Treated with Curative-Intent Resection: A Multicenter Study.Annals of surgical oncology · 2026Article
- Assessment prior to liver tumor resection: what a radiologist needs to know.Abdominal radiology (New York) · 2026Review
- A novel technique of spacer implantation and proton beam therapy for hilar cholangiocarcinoma: a case report.Frontiers in oncology · 2026Article
- Second-Line Treatment in cholangiocarcinoma - Current State of the Art and Future Perspectives.Current treatment options in oncology · 2025Review
- Applying liver transplant techniques in complex liver resection for patients with hilar cholangiocarcinoma: in situ hypothermic portal perfusion without VV bypass.World journal of surgical oncology · 2025Article
- Stent with radioactive seeds placement for obstructive hilar cholangiocarcinoma: comparison between unilateral and bilateral placement.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2025Article
- Article
- Diagnosis of Cholangiocarcinoma: The New Biological and Technological Horizons.Diagnostics (Basel, Switzerland) · 2025Review
- The global trend of intravenous anesthesia and tumors: a bibliometric and visualized study.Perioperative medicine (London, England) · 2025Article
- Preoperative assessment of longitudinal extent in hilar cholangiocarcinoma using noninvasive enhanced MR radiomics: a multicenter study.Frontiers in oncology · 2025Article
- A live single-cell reporter system reveals drug-induced plasticity of a cancer stem cell-like population in cholangiocarcinoma.Scientific reports · 2024Article
- Review
- Review
- Acute cholangitis withWorld journal of clinical cases · 2024Article
- Conversion Surgery Performed Following Durvalumab Combined With Gemcitabine and Cisplatin in Cholangiocarcinoma: A Case Report.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A consensus meeting of national experts from all major national hepatobiliary centres in the country was held on May 26, 2023, at the Pakistan Kidney and Liver Institute & Research Centre (PKLI & RC) after initial consultations with the experts. The Pakistan Society for the Study of Liver Diseases (PSSLD) and PKLI & RC jointly organised this meeting. This effort was based on a comprehensive literature review to establish national practice guidelines for hilar cholangiocarcinoma (hCCA). The consensus was that hCCA is a complex disease and requires a multidisciplinary team approach to best manage these patients. This coordinated effort can minimise delays and give patients a chance for curative treatment and effective palliation. The diagnostic and staging workup includes high-quality computed tomography, magnetic resonance imaging, and magnetic resonance cholangiopancreatography. Brush cytology or biopsy utilizing endoscopic retrograde cholangiopancreatography is a mainstay for diagnosis. However, histopathologic confirmation is not always required before resection. Endoscopic ultrasound with fine needle aspiration of regional lymph nodes and positron emission tomography scan are valuable adjuncts for staging. The only curative treatment is the surgical resection of the biliary tree based on the Bismuth-Corlette classification. Selected patients with unresectable hCCA can be considered for liver transplantation. Adjuvant chemotherapy should be offered to patients with a high risk of recurrence. The use of preoperative biliary drainage and the need for portal vein embolisation should be based on local multidisciplinary discussions. Patients with acute cholangitis can be drained with endoscopic or percutaneous biliary drainage. Palliative chemotherapy with cisplatin and gemcitabine has shown improved survival in patients with irresectable and recurrent hCCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.